Interesting Image

Metastatic Superscan in ¹⁸F PSMA PET/CT of a Patient with Prostate Carcinoma

10.4274/mirt.galenos.2023.68815

• Man Mohan Singh
• Shashwat Verma
• Lavish Kakkar
• Satyawati Deswal
• Priyamedha Bose Thakur

Received Date: 03.12.2022 Accepted Date: 02.04.2023 Mol Imaging Radionucl Ther 2024;33(1):38-39 PMID: 38390777

• Abstract
• Full Text
• Video - Image
• References
• 8
• 325

A biopsy-proven patient with prostate carcinoma aged 70 years was referred to the department of nuclear medicine for radionuclide-based therapy. His prostate-specific antigen levels were >1000 ng/mL, and prostatic magnetic resonance imaging showed an enlarged prostate with a heterogeneous signal and size 3.8x3.7x3.5 cm with few small heterogeneous nodular signals in the transition zone. He was scheduled for ¹⁸F prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scan before therapy. ¹⁸F PSMA PET/CT revealed PSMA-expressing prostate lesions (maximum standardized uptake value ~10.2) with extension into the urinary bladder along with bilateral supraclavicular, mediastinal, retrocrural, retroperitoneal, and pelvic lymph nodes and sclerotic lesions in the entire axial and appendicular skeleton.

Keywords: Superscan, prostate carcinoma, 18F PSMA PET/CT, 18F prostate-specific membrane antigen

Ethics

Informed Consent: The authors certify that they have obtained all appropriate patient consent forms.

Authorship Contributions

Surgical and Medical Practices: M.M.S., Concept: M.M.S., Design: S.D., Data Collection or Processing: L.K., P.B.T., Analysis or Interpretation: S.V., Literature Search: S.V., Writing: M.M.S.

Conflict of Interest: No conflicts of interest were declared by the authors.

Financial Disclosure: The authors declare that this study has received no financial support.

Images

1. Liu Y. Super-superscan on a bone scintigraphy. Clin Nucl Med 2011;36:227-228.
2. Buckley O, O’Keeffe S, Geoghegan T, Lyburn ID, Munk PL, Worsley D, Torreggiani WC. 99mTc bone scintigraphy superscans: a review. Nucl Med Commun 2007;28:521-527.
3. Chan M, Schembri GP. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT “superscan” in metastatic pancreatic neuroendocrine tumor. Clin Nucl Med 2017;42:108-109.
4. Chakraborty PS, Sharma P, Karunanithi S, Bal C, Kumar R. Metastatic superscan on (99m)Tc-MDP bone scintigraphy in a case of carcinoma colon: Common finding but rare etiology. Indian J Nucl Med 2014;29:158-159.
5. Agarwal KK, Tripathi M, Kumar R, Bal C. Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan. Indian J Nucl Med 2016;31:150-151.
6. Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, Treglia G. Diagnostic role of ¹⁸F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review. Diagnostics (Basel) 2021;11:552.
7. Ferrari M, Treglia G. ¹⁸F-PSMA-1007 pET in biochemical recurrent prostate cancer: an updated meta-analysis. Contrast Media Mol Imaging 2021;2021:3502389.
8. Wang Z, Zheng A, Li Y, Dong W, Liu X, Yuan W, Gao F, Duan X. ¹⁸F-PSMA-1007 PET/CT performance on risk stratification discrimination and distant metastases prediction in newly diagnosed prostate cancer. Front Oncol 2021;11:759053.